Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Singapore ETF (EWS) vs Cassava Sciences Inc (FLNA) Price & Performance

iShares MSCI Singapore ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Singapore ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Singapore ETF trades at $33.68, while Cassava Sciences Inc trades at $0.93 (market cap $47.75M). The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

EWSFLNA
Sector
Broad Market / FactorHealth
52-Week High
$33.92$4.64
52-Week Low
$26.71$0.87
Market Cap
$47.75M
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Singapore ETF

EWS (iShares MSCI Singapore ETF) trades at $33.66, up 1.48% today and hitting a new 52-week high. Technical indicators show a bullish moving average consensus but overbought RSI signals. The ETF benefits from Singapore's economic resilience and AI-driven growth momentum, with institutional buying from firms like Amundi. Dividend yield remains attractive at 3.97% with consistent payout history.

Outlook remains positive given Singapore's market reforms and AI infrastructure growth, though concentrated financial sector exposure (54%) poses sector-specific risks. Near-term resistance at $34 may challenge further upside without fundamental catalysts. The ETF offers strategic Asian diversification but requires monitoring of regional economic developments.

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Singapore ETF

EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.

Read more on EWS

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA